Interferon alfa therapy in an infant with juvenile chronic myelogenous leukemia

Roberto Toraldo, Francesco Vetrano, Vito Pistoia, Carlo Tolone, Gianfranco Canino, Michele D'Avanzo, Ferdinando Lafusco

Research output: Contribution to journalArticle

Abstract

We describe an infant with juvenile chronic myelogenous leukemia (JCML), the diagnosis of which was made by the characteristic clinical and hematologic findings. The absence of a related HLA - compatible donor for bone marrow transplantation coupled with the awareness that chemotherapy is usually ineffective prompted our decision to treat the patient with lymphoblastoid interferon-α [αLy)-IFN]. During the 26-month course of treatment with αLy)-IFN an incomplete regression of hematologic and clinical findings was achieved. The above results, along with the easy administration and absence of considerable side effects, suggest that αLy)-IFN may be a useful therapeutic tool in patients affected by JCML awaiting bone marrow transplantation.

Original languageEnglish
Pages (from-to)189-194
Number of pages6
JournalPediatric Hematology and Oncology
Volume12
Issue number2
DOIs
Publication statusPublished - 1995

Keywords

  • Interferon-α
  • Juvenile chronic myelogenous leukemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology
  • Cancer Research
  • Management of Technology and Innovation

Fingerprint Dive into the research topics of 'Interferon alfa therapy in an infant with juvenile chronic myelogenous leukemia'. Together they form a unique fingerprint.

  • Cite this

    Toraldo, R., Vetrano, F., Pistoia, V., Tolone, C., Canino, G., D'Avanzo, M., & Lafusco, F. (1995). Interferon alfa therapy in an infant with juvenile chronic myelogenous leukemia. Pediatric Hematology and Oncology, 12(2), 189-194. https://doi.org/10.3109/08880019509029554